• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2021, Vol. 38 ›› Issue (2): 115-121.

• 药品评价 • 上一篇    下一篇

附子成方治疗缓慢性心律失常的Meta分析

 谢晓青1, 刘杰1, 段宝忠1, 张海珠1, 夏从龙1,2*   

  1. 1. 大理大学药学院, 云南 大理 671000;
    2. 云南省高校滇西道地药材资源开发重点实验室, 云南 大理 671000
  • 收稿日期:2021-01-05 修回日期:2021-02-10 出版日期:2021-04-28 发布日期:2021-04-28
  • 基金资助:
    大理州科技计划重大项目(编号:D2019NA03)

A Meta-Analysis of Aconite in Treating Bradycardia

XIE Xiao-qing1, LIU jie1, DUAN Bao-zhong1, ZHANG Hai-zhu1, XIA Cong-long1,2*   

  1. 1. College of Pharmacy, Dali University, Yunnan Dali 671000, China;
    2. Key Laboratory of Yunnan Provincial Higher Education Institution for Development of Yunnan Dali Medicinal Materials Resources,
         Yunnan Dali 671000, China
  • Received:2021-01-05 Revised:2021-02-10 Online:2021-04-28 Published:2021-04-28

摘要: 目的:系统评价附子成方治疗缓慢性心律失常的疗效和安全性。方法:计算机检索 PubMed、CNKI、WANFANG、VIP等数据库中收录的附子成方治疗缓慢性心律失常的随机对照试验(RCTs)(检索时间截至2020年12月)。按Cochrane系统评价的方法评价纳入研究的质量,采用RevMan5.3软件进行Meta分析。结果: 共纳入16个RCT,包括1 515例受试者。Meta分析结果显示:在疗效方面,附子成方组的有效性优于对照组,[RR=1.30,95%CI(1.23,1.38),P<0.000 01],两组差异具有统计学意义;同时改善患者中医证候积分[MD=-0.32,95%CI(-0.70,0.06),P=0.10]、基础心率[MD=-0.96,95%CI(-2.87,0.95),P=0.33]、24h平均心率[MD=-0.42,95%CI(-0.93,0.09),P=0.11]和24h最慢心率[MD=0.40,95%CI(-0.45,1.24),P=0.36]。安全性方面与对照组相比,附子成方组有显著差异,[RR=0.41,95%CI(0.18,0.93),P=0.03]。结论: 西医常规治疗基础上加用附子成方能提高缓慢性心律失常的治疗效果,且安全性较好,为附子成方的临床用药提供依据和参考。

关键词: font-size:medium, ">附子;缓慢性心律失常;随机对照试验;Meta分析

Abstract: Objective: To systematically evaluate the efficacy and safety of aconite in the treatment of bradycardia. Methods: Databases of PubMed, CNKI, WAN FANG, VIP were systematically searched for randomized controlled trials (RCTs) focused on adding aconite in treating bradycardia(the establishment of each database to December 2020). The quality of the included studies was evaluated according to the method of Cochrane systematic review, and the RevMan5.3 software was used for Meta-analysis. Results: A total of 16 RCT was included, including 1 515 subjects. Meta-analysis results show that: in terms of efficacy, the aconite group is more effective than the control group, [RR=1.30, 95%CI(1.23,1.38), P<0.000 01], the difference between the two groups is statistically significant. At the same time, patients′ TCM symptom score [MD=-0.32, 95%CI(-0.70,0.06), P=0.10], basal heart rate [MD=-0.96, 95%CI(-2.87,0.95), P=0.33], 24 h average heart rate [MD=-0.42, 95%CI(-0.93, 0.09), P=0.11] and 24 h slowest heart rate were improved [MD=0.40, 95%CI(-0.45, 1.24), P=0.36]. In terms of safety, compared with the control group, the aconite group had significant differences, [RR=0.41, 95%CI(0.18, 0.93), P=0.03]. Conclusion: The results showed that the combination of aconite based on conventional western medicine treatment can improve the treatment effect of bradyarrhythmia, and it has better safety, which provides a basis and reference for the clinical use of aconite.
   

Key words: font-size:medium, ">Aconite; Bradycardia; Randomized controlled trial; Meta-analysis

中图分类号: